- Home
- LLYVK vs RYTM Comparison
LLYVK vs RYTM Comparison
Compare LLYVK & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLYVK
- RYTM
- Stock Information
- Founded
- LLYVK 1991
- RYTM 2008
- Country
- LLYVK United States
- RYTM United States
- Employees
- LLYVK N/A
- RYTM N/A
- Industry
- LLYVK Broadcasting
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- LLYVK Industrials
- RYTM Health Care
- Exchange
- LLYVK Nasdaq
- RYTM Nasdaq
- Market Cap
- LLYVK 7.6B
- RYTM 6.4B
- IPO Year
- LLYVK N/A
- RYTM 2017
- Fundamental
- Price
- LLYVK $78.63
- RYTM $108.99
- Analyst Decision
- LLYVK
- RYTM Strong Buy
- Analyst Count
- LLYVK 0
- RYTM 13
- Target Price
- LLYVK N/A
- RYTM $118.46
- AVG Volume (30 Days)
- LLYVK 312.2K
- RYTM 748.3K
- Earning Date
- LLYVK 01-01-0001
- RYTM 11-04-2025
- Dividend Yield
- LLYVK N/A
- RYTM N/A
- EPS Growth
- LLYVK N/A
- RYTM N/A
- EPS
- LLYVK N/A
- RYTM N/A
- Revenue
- LLYVK N/A
- RYTM $174,334,000.00
- Revenue This Year
- LLYVK N/A
- RYTM $46.10
- Revenue Next Year
- LLYVK $10.89
- RYTM $63.02
- P/E Ratio
- LLYVK N/A
- RYTM N/A
- Revenue Growth
- LLYVK N/A
- RYTM 54.92
- 52 Week Low
- LLYVK $60.55
- RYTM $45.91
- 52 Week High
- LLYVK $102.62
- RYTM $116.00
- Technical
- Relative Strength Index (RSI)
- LLYVK 31.80
- RYTM 59.25
- Support Level
- LLYVK $78.01
- RYTM $98.52
- Resistance Level
- LLYVK $81.74
- RYTM $108.99
- Average True Range (ATR)
- LLYVK 2.61
- RYTM 4.59
- MACD
- LLYVK -0.55
- RYTM 0.65
- Stochastic Oscillator
- LLYVK 11.72
- RYTM 92.13
About LLYVK Liberty Media Corporation
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.